|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0026032,
umls-concept:C0030705,
umls-concept:C0035191,
umls-concept:C0087111,
umls-concept:C0123931,
umls-concept:C0205373,
umls-concept:C0303596,
umls-concept:C0494165,
umls-concept:C0521115,
umls-concept:C1527249
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2009-8-31
|
|
pubmed:abstractText |
Liver metastases are the principal cause of death in patients with advanced colorectal cancer (CRC). Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation. Radioembolization with yttrium-90 microspheres has demonstrated increased response and survival rates when given with fluorouracil chemotherapy. This study's goal was to evaluate the maximum-tolerated dose of concomitant irinotecan and radioembolization in fluorouracil-refractory patients with CRC hepatic metastases.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BowerGeoffrey DGD,
pubmed-author:BriggsGregory MGM,
pubmed-author:GeorgeJacobJ,
pubmed-author:GoldsteinDavidD,
pubmed-author:OlverIan NIN,
pubmed-author:PavlakisNickN,
pubmed-author:PriceDavidD,
pubmed-author:RossleighMonica AMA,
pubmed-author:TapnerMichael JMJ,
pubmed-author:TaylorD JamesDJ,
pubmed-author:van HazelGuy AGA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4089-95
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19652069-Adult,
pubmed-meshheading:19652069-Aged,
pubmed-meshheading:19652069-Antimetabolites, Antineoplastic,
pubmed-meshheading:19652069-Australia,
pubmed-meshheading:19652069-Brachytherapy,
pubmed-meshheading:19652069-Camptothecin,
pubmed-meshheading:19652069-Chemotherapy, Adjuvant,
pubmed-meshheading:19652069-Colorectal Neoplasms,
pubmed-meshheading:19652069-Disease-Free Survival,
pubmed-meshheading:19652069-Drug Administration Schedule,
pubmed-meshheading:19652069-Drug Resistance, Neoplasm,
pubmed-meshheading:19652069-Enzyme Inhibitors,
pubmed-meshheading:19652069-Female,
pubmed-meshheading:19652069-Fluorouracil,
pubmed-meshheading:19652069-Humans,
pubmed-meshheading:19652069-Infusions, Intravenous,
pubmed-meshheading:19652069-Liver Neoplasms,
pubmed-meshheading:19652069-Male,
pubmed-meshheading:19652069-Maximum Tolerated Dose,
pubmed-meshheading:19652069-Microspheres,
pubmed-meshheading:19652069-Middle Aged,
pubmed-meshheading:19652069-Radiopharmaceuticals,
pubmed-meshheading:19652069-Radiotherapy, Adjuvant,
pubmed-meshheading:19652069-Time Factors,
pubmed-meshheading:19652069-Topoisomerase I Inhibitors,
pubmed-meshheading:19652069-Treatment Outcome,
pubmed-meshheading:19652069-Yttrium Isotopes
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
|
|
pubmed:affiliation |
Perth Radiologic Clinic, Mount Medical Centre, Perth, Western Australia, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
